In the time since autologous chimeric antigen receptor T-cell (CAR-T) therapies became available, with just one dose, many patients who believed they were out of options have benefited from the therapy’s unprecedented outcomes. Today, CAR-T manufacturers are exploring how to produce more therapies to meet patient demand and ultimately save lives.
In this new ZS white paper, we look at current manufacturing pain points while introducing a potential solution: decentralized manufacturing. Borrowed from other industries, decentralized manufacturing is often described as the process of moving production away from a central facility to multiple sites closer to customers.
Read the white paper to learn how decentralized manufacturing can help CAR-T manufactures save on costs while producing more therapies faster.
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
